zavegepant   Click here for help

GtoPdb Ligand ID: 11513

Synonyms: BHV-3500 | BMS-742413 | BMS742413 | Zavzpret®
Approved drug
zavegepant is an approved drug (FDA (2023))
Compound class: Synthetic organic
Comment: Zavegepant is a CGRP receptor antagonist [1,3], that was developed as a drug to treat and/or prevent migraine. It was designed for intranasal administration.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 120.67
Molecular weight 638.37
XLogP 3.56
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CN1CCC(CC1)N1CCN(CC1)C(=O)[C@H](NC(=O)N1CCC(CC1)c1cc2ccccc2[nH]c1=O)Cc1cc(C)c2c(c1)cn[nH]2
Isomeric SMILES CN1CCC(CC1)N1CCN(CC1)C(=O)[C@H](NC(=O)N1CCC(CC1)c1cc2ccccc2[nH]c1=O)Cc1cc(C)c2c(c1)cn[nH]2
InChI InChI=1S/C36H46N8O3/c1-24-19-25(20-28-23-37-40-33(24)28)21-32(35(46)43-17-15-42(16-18-43)29-9-11-41(2)12-10-29)39-36(47)44-13-7-26(8-14-44)30-22-27-5-3-4-6-31(27)38-34(30)45/h3-6,19-20,22-23,26,29,32H,7-18,21H2,1-2H3,(H,37,40)(H,38,45)(H,39,47)/t32-/m1/s1
No information available.
Summary of Clinical Use Click here for help
Zavegepant (as BHV-3500) was evaluated as a migraine prophylactic drug by Biohaven Pharmaceuticals. It was the first CGRP receptor antagonist nasal spray for the acute treatment of migraine, with its FDA approval granted in March 2023 [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04408794 Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine Phase 2/Phase 3 Interventional Biohaven Pharmaceuticals, Inc.
NCT04571060 Randomized Trial in Adult Subjects With Acute Migraines Phase 3 Interventional Biohaven Pharmaceuticals, Inc.
NCT04346615 Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen Phase 2/Phase 3 Interventional Biohaven Pharmaceuticals, Inc.
NCT03872453 Acute Treatment Trial in Adult Subjects With Migraines Phase 2/Phase 3 Interventional Biohaven Pharmaceuticals, Inc.
NCT04804033 A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention Phase 2/Phase 3 Interventional Biohaven Pharmaceuticals, Inc.